Intraoperative Near-Infrared Fluorescence Imaging using indocyanine green in colorectal carcinomatosis surgery: Proof of concept

European Journal of Surgical Oncology

Volumn 42, Issue 12, 2016, Pages 1931-1937

  Barabino, G ^a,b,c   Klein, J P ^a   Porcheron, J ^b   Grichine, A ^c   Coll, J L ^c   Cottier, M ^a  

^a Jean Monnet University   (France)

^b UNIVERSITÉ JEAN MONNET   (France)

^c INSTITUT ALBERT BONNIOT   (France)

Author keywords

Colorectal peritoneal carcinomatosis; Indocyanine green; Intraoperative Near Infrared Imaging Fluorescence System; Surgery

Indexed keywords

INDOCYANINE GREEN; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CETUXIMAB; COLORING AGENT;

ABSENCE OF COMPLICATIONS; ABSENCE OF SIDE EFFECTS; AGED; ARTICLE; CAMERA; CANCER SURGERY; CARCINOMATOSIS; CLINICAL ARTICLE; COLORECTAL CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; FLUORESCENCE IMAGING; FLUORESCENCE IMAGING SYSTEM; HUMAN; INTRAOPERATIVE PERIOD; MALE; NEAR INFRARED FLUORESCENCE IMAGING; NEAR INFRARED IMAGING SYSTEM; PILOT STUDY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SURGICAL MORTALITY; YOUDEN INDEX; ADJUVANT CHEMORADIOTHERAPY; ADJUVANT CHEMOTHERAPY; CANCER STAGING; CARCINOMA; COLORECTAL TUMOR; DIAGNOSTIC IMAGING; MIDDLE AGED; NEOADJUVANT THERAPY; PARENTERAL DRUG ADMINISTRATION; PATHOLOGY; PERITONEAL NEOPLASMS; PERITONEUM; PEROPERATIVE CARE; PROCEDURES; SURGERY; THERMOTHERAPY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BEVACIZUMAB; CARCINOMA; CETUXIMAB; CHEMORADIOTHERAPY, ADJUVANT; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; COLORING AGENTS; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; INDOCYANINE GREEN; INFUSIONS, PARENTERAL; INTRAOPERATIVE CARE; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; OPTICAL IMAGING; PERITONEAL NEOPLASMS; PERITONEUM; PILOT PROJECTS;

EID: 85003422045     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2016.06.389     Document Type: Article

References (43)

1. 1 Chu, D.Z., Lang, N.P., Thompson, C., Osteen, P.K., Westbrook, K.C., Peritoneal carcinomatosis in non-gynecologic malignancies: a prospective study of prognostic factors. Cancer 63 (1989), 364–367.
2. 2 Sadeghi, B., Arvieux, C., Glehen, O., et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of EVOCAPE 1 multicentric prospective study. Cancer 88 (2000), 358–363.
3. 3 Jayne, D.G., Fook, S., Loi, C., Seow-Choen, F., Peritoneal carcinomatosis from colorectal cancer. Br J Surg 89 (2002), 1545–1550.
4. 4 Glehen, O., Sugarbaker, P.H., Elias, D., et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 22 (2004), 3284–3292.
5. 5 Da Silva, R.G., Sugarbaker, P.H., Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer. J Am Coll Surg 203 (2006), 878–886.
6. 6 Verwaal, V.J., Van Ruth, S., Witkamp, A., Boot, H., Van Slooten, G., Zoetmulder, F.A., Long-term survival of peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol 12 (2005), 65–71.
7. 7 Elias, D., Raynard, B., Farkhondeh, F., et al. Long-term survival of peritoneal carcinomatosis of colorectal origin. Gastroenterol Clin Biol 30 (2006), 1200–1204.
8. 8 Quere, P., Facy, O., Manfredi, S., et al. Epidemiology, management, and survival of peritoneal carcinomatosis from colorectal cancer: a population-based study. Dis Colon Rectum 58:8 (2015), 743–752.
9. 9 Hermanek, P., Wittekind, C., Residual tumor (R) classification and prognosis. Semin Surg Oncol 10 (1994), 12–20.
10. 10 Begossi, G., Gonzalez-Moreno, S., Ortega-Perez, G., Fon, L.J., Sugarbaker, P.H., Cytoreduction and intraperitoneal chemotherapy for the management of peritoneal carcinomatosis, sarcomatosis and mesothelioma. Eur J Surg Oncol 28 (2002), 80–87.
11. 11 Pfannenberg, C., Konigsrainer, I., Aschoff, P., et al. (18)F-FDG-PET/CT to select patients with peritoneal carcinomatosis for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 16:5 (2009), 1295–1303.
12. 12 Dromain, C., Leboulleux, S., Auperin, A., et al. Staging of peritoneal carcinomatosis: enhanced CT vs. PET/CT. Abdom Imaging 33 (2008), 87–93.
13. 13 Sugarbaker, P.H., Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. Semin Surg Oncol 14 (1998), 254–261.
14. 14 Esquivel, J., Cytoreductive surgery for peritoneal malignancies development of standards of care for the community. Surg Oncol Clin N Am 16 (2007), 653–666.
15. 15 Frangioni, J., In vivo near-infrared fluorescence imaging. Curr Opin Chem Biol 7 (2003), 626–634.
16. 16 Gioux, S., Choi, H.S., Frangioni, J.V., Image-guided surgery using invisible near-infrared light: fundamentals of clinical translation. Mol Imaging 9 (2010), 237–255.
17. 17 Troyan, S.L., Kianzad, V., Gibbs-Strauss, S.L., et al. The FLARE intraoperative near-infrared fluorescence imaging system: a first-in-human clinical trial in breast cancer sentinel lymph node mapping. Ann Surg Oncol 16 (2009), 2943–2952.
18. 18 Kim, S., Lim, Y.T., Soltesz, E.G., et al. Near-infrared fluorescent type II quantum dots for sentinel lymph node mapping. Nat Biotechnol 22 (2004), 93–97.
19. 19 Schaafsma, B.E., Mieog, J.S.D., Hutteman, M., et al. The clinical use of indocyanine green as a near-infrared fluorescent contrast agent for image-guided oncologic surgery. J Surg Oncol 104 (2011), 323–332.
20. 20 Van der Vorst, J.R., Schaafsma, B.E., Verbeek, F.P., et al. Near-infrared fluorescence sentinel lymph node mapping of the oral cavity in head and neck cancer patients. Oral Oncol 49 (2013), 15–19.
21. 21 Van Dam, G.M., Themelis, G., Crane, L.M.A., et al. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results. Nat Med 18 (2011), 1315–1319.
22. 22 Altinoğlu, E.I., Russin, T.J., Kaiser, J.M., et al. Near-infrared emitting fluorophore-doped calcium phosphate nanoparticles for in vivo imaging of human breast cancer. ACS Nano 2 (2008), 2075–2084.
23. 23 Maeda, H., Wu, J., Sawa, T., Matsumura, Y., Hori, K., Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65 (2000), 271–284.
24. 24 Ranganathan, R., Madanmohan, S., Kesavan, A., et al. Nanomedicine: towards development of patient-friendly drug-delivery systems for oncological applications. Int J Nanomedicine 7 (2012), 1043–1060.
25. 25 Ishizawa, T., Fukushima, N., Shibahara, J., et al. Real-time identification of liver cancers by using indocyanine green fluorescent imaging. Cancer 115:11 (2009), 2491–2504.
26. 26 Miyashiro, I., Miyoshi, N., Hiratsuka, M., et al. Detection of sentinel node in gastric cancer surgery by indocyanine green fluorescence imaging: comparison with infrared imaging. Ann Surg Oncol 15:6 (2008), 1640–1643.
27. 27 Gioux, S., Coutard, J.G., Berger, M., et al. FluoSTIC: miniaturized fluorescence image-guided surgery system. J Biomed Opt, 17(10), 2012 Oct, 109802.
28. 28 Youden, W.J., Index for rating diagnostic tests. Cancer 3 (1950), 32–35.
29. 29 Polom, K., Murawa, D., Rho, Y.S., Nowaczyk, P., Hunerbein, M., Murawa, P., Current trends and emerging future of indocyanine green usage in surgery and oncology. Cancer 117:21 (2011), 4812–4822.
30. 30 Chi, C., Du, Y., Ye, J., et al. Intraoperative imaging-guided cancer surgery: from current fluorescence molecular imaging methods to future multi-modality imaging technology. Theranostic 4:11 (2014), 1072–1084.
31. 31 Van der Vorst, J.R., Schaafsma, B.E., Verbeek, F.P.R., et al. Near-infrared fluorescence sentinel lymph node mapping of the oral cavity in head and neck cancer patients. Oral Oncol 49 (2013), 15–19.
32. 32 Hirche, C., Murawa, D., Mohr, Z., Kneif, S., Hunerbein, M., ICG fluorescence-guided sentinel node biopsy for axillary nodal staging in breast cancer. Breast Cancer Res Treat 121 (2010), 373–378.
33. 33 Gilmore, D.M., Khullar, O.V., Gioux, S., et al. Effective low-dose escalation of indocyanine green for near-infrared fluorescent sentinel lymph node mapping in melanoma. Ann Surg Oncol 20 (2013), 2357–2363.
34. 34 Yamashita, S., Tokuishi, K., Miyawaki, M., et al. Sentinel node navigation surgery by thoracoscopic fluorescence imaging system and molecular examination in non-small cell lung cancer. Ann Surg Oncol 19 (2012), 728–733.
35. 35 Kubota, K., Yoshida, M., Kuroda, J., Okada, A., Ohta, K., Kitajima, M., Application of the HyperEye Medical System for esophageal cancer surgery: a preliminary report. Surg Today 43 (2013), 215–220.
36. 36 Fujita, T., Seshimo, A., Kameoka, S., Detection of sentinel nodes in gastric cancer by indocyanine green fluorescence imaging. Hepatogastroenterology 59 (2012), 2213–2216.
37. 37 Schaafsma, B.E., van der Vorst, J.R., Gaarenstroom, K.N., et al. Randomized comparison of near-infrared fluorescence lymphatic tracers for sentinel lymph node mapping of cervical cancer. Gynecol Oncol 127 (2012), 126–130.
38. 38 Hirche, C., Mohr, Z., Kneif, S., et al. Ultrastaging of colon cancer by sentinel node biopsy using fluorescence navigation with indocyanine green. Int J Colorectal Dis 27 (2012), 319–324.
39. 39 Holloway, R.W., Bravo, R.A.M., Rakowski, J.A., et al. Detection of sentinel lymph nodes in patients with endometrial cancer undergoing robotic-assisted staging: a comparison of colorimetric and fluorescence imaging. Gynecol Oncol 126 (2012), 25–29.
40. 40 Schaafsma, B.E., Verbeek, F.P.R., Peters, A.A.W., et al. Near-infrared fluorescence sentinel lymph node biopsy in vulvar cancer: a randomised comparison of lymphatic tracers. BJOG 120 (2013), 758–764.
41. 41 Liberale, G., Vankerckhove, S., Caldon, M.G., et al. Fluorescence imaging after indocyanine green injection for detection of peritoneal metastases in patients undergoing cytoreductive surgery for peritoneal carcinomatosis from colorectal cancer. Ann Surg, 2016; 5 Jan.
42. 42 Maeda, H., The link between infection and cancer: tumor vasculature, free radicals, and drug delivery to tumors via the EPR effect. Cancer Sci 104 (2013), 779–789.
43. 43 Maeda, H., Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting. Proc Jpn Acad Ser B Phys Biol Sci 88 (2012), 53–71.